No Big Blockbuster Bailouts Act

Bill Number

S. 3019

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-10-21: Read twice and referred to the Committee on Finance.

Last Updated

2025-12-02T17:59:15Z

AI-Generated Summary

Purpose

The "No Big Blockbuster Bailouts Act" (S. 3019) aims to modify how certain drugs for rare diseases—known as orphan drugs—are handled under the Medicare Drug Price Negotiation Program. This program, established by the Inflation Reduction Act, allows the government to negotiate lower prices for high-cost prescription drugs covered by Medicare. The bill seeks to provide additional protection for orphan drugs that are used solely for rare conditions, by adjusting the criteria that determine whether they can be excluded from price negotiations.

Key Provisions

• Short Title: The legislation is titled the "No Big Blockbuster Bailouts Act."
• Amendment to Social Security Act: It revises Section 1192(e) of Title XI of the Social Security Act, which governs exclusions from the Medicare Drug Price Negotiation Program.
• Removes certain existing subparagraphs and redesignates others for clarity.
• Introduces a new rule for orphan drugs: Drugs designated by the FDA for treating one or more rare diseases or conditions (as defined under the Federal Food, Drug, and Cosmetic Act), where the only approved use(s) are for such rare conditions, will have their exclusion threshold raised.
• Threshold Adjustment: Under the current program, a single-source drug (one without generic competition) is generally excluded from negotiation if Medicare spending on it is $200 million or less in a given year. For qualifying orphan drugs, this threshold is increased to $400 million.
• Effective Date: The changes apply to "initial price applicability years" (the years when negotiated prices first take effect) starting on or after January 1, 2028.

Significant Changes to Existing Law

• Current Law (Pre-Amendment): Orphan drugs receive some exclusions from negotiation, but the spending threshold for exclusion is uniformly $200 million for most drugs, with specific rules limiting broader protections for drugs that have non-rare disease indications.
• Key Change: The bill doubles the exclusion threshold to $400 million exclusively for orphan drugs whose sole approved indications are for rare diseases. This narrows the scope to "pure" orphan drugs, preventing companies from using orphan status to shield high-revenue "blockbuster" drugs (those with sales from non-rare uses) from negotiation.
• Structural Tweaks: It streamlines the section by removing redundant paragraphs and inserting language to reference the new threshold, ensuring it applies "subject to" other exclusion rules.

Potential Impacts

• On Government Agencies: The Centers for Medicare & Medicaid Services (CMS) may negotiate prices for fewer purely orphan drugs in the short term due to the higher threshold, potentially increasing Medicare's overall drug spending. However, it could reduce administrative complexity by clarifying rules for orphan drugs.
• On Citizens: Medicare beneficiaries with rare diseases may benefit from continued access to these drugs without immediate price reductions, avoiding potential supply disruptions. Broader Medicare enrollees and taxpayers could face higher program costs, as more spending on orphan drugs remains unnegotiated.
• On International Relations: Minimal direct impact, though it may influence global pharmaceutical pricing strategies, as U.S. Medicare negotiations often set benchmarks for international drug prices.
• Overall: Could lead to higher Medicare expenditures (estimated in billions over time if thresholds allow more exclusions), but promotes stability for treatments of rare conditions affecting small patient populations.

Main Stakeholders Affected

• Pharmaceutical Companies: Developers of orphan drugs gain extended protection from price negotiations for drugs with higher Medicare sales (up to $400 million), particularly small biotech firms focused on rare diseases. Larger companies with "blockbuster" drugs may face stricter scrutiny if those drugs have non-orphan uses.
• Patients and Advocacy Groups: Individuals with rare diseases (about 30 million Americans) and groups like the National Organization for Rare Disorders benefit from preserved drug availability and innovation incentives.
• Government and Payers: CMS and Medicare trustees may see increased budget pressures; taxpayers fund the program's costs.
• Healthcare Providers: Doctors and hospitals treating rare conditions could maintain access to specialized drugs without negotiation-related shortages.

Notable Legal, Constitutional, or Political Implications

• Legal Implications: The amendment operates within Congress's authority under the Constitution's Commerce Clause to regulate interstate commerce, including healthcare and drug pricing. It builds on the Inflation Reduction Act without challenging FDA orphan drug designations, reducing litigation risks from drugmakers.
• Constitutional Implications: None significant; it aligns with established federal powers over Social Security and Medicare, avoiding First Amendment or takings clause issues by focusing on spending thresholds rather than mandating price cuts.
• Political Implications: Introduced by Senators Welch, Wyden, and Cortez Masto (Democrats), the bill balances drug affordability goals with support for rare disease research, potentially appealing to bipartisan rare disease advocates. The title critiques "bailouts" for big pharma, signaling intent to close loopholes, but the higher threshold may draw criticism from cost-control advocates for favoring industry protections. Referred to the Senate Finance Committee, its passage could influence future drug pricing reforms.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Welch, Peter [D-VT]

Cosponsors (2)

Sen. Wyden, Ron [D-OR], Sen. Cortez Masto, Catherine [D-NV]

Recent Actions

• 2025-10-21: Read twice and referred to the Committee on Finance.
• 2025-10-21: Introduced in Senate

Bill Versions

• No Big Blockbuster Bailouts Act — issued 2025-10-21 — PDF (3 pages)